AstraZeneca lifts forecast after strong Q3, signs $2B deal for obesity drug (NASDAQ:AZN)

Roland Magnusson/iStock Editorial via Getty Images

AstraZeneca (NASDAQ:AZN) posted around 5% Y/Y higher revenues to $11.5B for Q3, missing consensus estimates. The top-line was weighed down by the continued decline in COVID-19 medicines, while revenue from non-COVID drugs rose 12%.

The biotechnology firm saw double-digit growth

Related Posts